Orexo Publishes Q3 2026 Earnings Call Transcript
Bitget2026/10/22 12:57- Orexo outlined its shift toward partner-funded development at its Q3 2026 earnings call, attended by CEO Nikolaj Sorensen and CFO Fredrik Jarrsten.
- Management targets cash runway beyond 2027 without partnership income, supported by a rights issue; quarter-end own cash totaled SEK 62 million.
- Izipry’s FDA resubmission on September 29 carries an expected six-month review, targeting US approval by the end of Q1 2027.
- OX640’s first pivotal trial is scheduled to begin in Q4, with results expected in the first half of 2027; partnering discussions continue.
- A proposed Justice Department settlement would require payments of up to $4 million over several years; principal terms are agreed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

AI-driven selloff boosts safe-haven demand; yen and Swiss franc lead major currencies as the US dollar declines
On Friday, as concerns grew over the sustainability of the AI frenzy, both the Japanese yen and the Swiss franc rose 0.6% against the US dollar, with the yen set to record its largest single-day gain in nearly a month. Analysts noted that when the market shifts toward risk aversion, unwinding of yen carry trades tends to strengthen the yen, while the Swiss franc has long served as a balance sheet hedging tool at the institutional level.

S&P 500 Index falls below 7,000 points
